Encorafenib

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Encorafenib
   1. Pharmacist Assessment Report
   2. Encorafenib: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Encorafenib: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Encorafenib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
colorectal neoplasms	licence in another country
melanoma	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
metastatic melanoma

Australia Market Information

Licence	Product	Dosage form	Status
11937G	Braftovi	Capsule 50 mg	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BRAF kinase inhibitor), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI. Skin examination is advisable, as BRAF inhibitors can cause new cutaneous malignancies
Handling Protection	Please refer to the PI and local handling policies

Safety Considerations

• Drug Interactions: 100 interactions were identified in the DDI screen (20 shown in the data compiled for this report). Major-level interactions include:
  • Aprepitant
  • Dexamethasone
  • Clarithromycin
  • Dolasetron
  • Cisapride

  Moderate-level interactions include:

  • Famotidine
  • Metformin
  • Loperamide
  • Bisacodyl
  • Saxagliptin
  • Empagliflozin
  • Linagliptin
  • Glyburide
  • Granisetron
  • Eliglustat
  • Fidaxomicin
  • Several laxatives and bowel-preparation agents
• Paradoxical MAPK activation signal: Case reports describe new melanomas arising during BRAF inhibitor therapy (PMIDs 41774417, 40878071, 31804055). This supports regular skin surveillance and confirmation of BRAF status.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---